JPMorgan Chase & Co. Lowers iTeos Therapeutics (NASDAQ:ITOS) Price Target to $32.00

iTeos Therapeutics (NASDAQ:ITOS – Get Rating) had its price objective lowered by analysts at JPMorgan Chase & Co. from $34.00 to $32.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 126.63% from the stock’s previous close.

Separately, Wedbush lowered their price objective on iTeos Therapeutics from $45.00 to $33.00 and set an “outperform” rating for the company in a research note on Thursday.

iTeos Therapeutics Stock Down 4.4 %

Shares of NASDAQ ITOS opened at $14.12 on Thursday. iTeos Therapeutics has a fifty-two week low of $13.81 and a fifty-two week high of $37.26. The business has a 50 day moving average price of $18.81 and a two-hundred day moving average price of $19.42. The firm has a market cap of $502.39 million, a PE ratio of 2.05 and a beta of 1.42.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. State of Tennessee Treasury Department lifted its holdings in iTeos Therapeutics by 10.4% during the 4th quarter. State of Tennessee Treasury Department now owns 15,560 shares of the company’s stock worth $304,000 after buying an additional 1,468 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of iTeos Therapeutics by 2.6% in the 4th quarter. Legal & General Group Plc now owns 59,065 shares of the company’s stock worth $1,154,000 after purchasing an additional 1,511 shares during the last quarter. Morgan Stanley lifted its holdings in shares of iTeos Therapeutics by 1.6% in the 4th quarter. Morgan Stanley now owns 846,859 shares of the company’s stock worth $16,539,000 after purchasing an additional 12,965 shares during the last quarter. Endurant Capital Management LP bought a new stake in shares of iTeos Therapeutics in the 4th quarter worth approximately $411,000. Finally, Alps Advisors Inc. lifted its holdings in shares of iTeos Therapeutics by 13.3% in the 4th quarter. Alps Advisors Inc. now owns 39,697 shares of the company’s stock worth $775,000 after purchasing an additional 4,652 shares during the last quarter.

iTeos Therapeutics Company Profile

(Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.